Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
TG Therapeutics, Inc.

TG Therapeutics, Inc. (TGTX) Stock Overview

Explore TG Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

TGTX●NASDAQ
HealthcareBiotechnology
$65.76
$1.50(2.33%)
U.S. Market opens in 4h 13m

TG Therapeutics, Inc. (TGTX)

Meyka AI Score

Z

Key Financials

Market Cap10.1B
P/E Ratio86.99
EPS (TTM)$2.76
ROE0.18%
Fundamental Analysis

AI Price Forecasts

1 Month$52.34
3 Months$65.14
1 Year Target$48.47

TGTX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of TG Therapeutics, Inc. (NASDAQ: TGTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, TG Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of TGTX on the NASDAQ shows an RSI of 69.96, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $48.47 for the NASDAQ listing.

Key metrics behind TG Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 86.99 and a market capitalization of 10.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TGTX on the NASDAQ.

Price Performance (NASDAQ: TGTX)

1-Day Change
2.33%
5-Day Change
13.40%
1-Month Change
18.76%
3-Month Change
31.78%
6-Month Change
52.43%
Year-to-Date (YTD) Change
120.60%
1-Year Change
111.38%
3-Year Change
541.56%
5-Year Change
98.25%
All-Time (Max) Change
-70.77%

Contact Information

https://www.tgtherapeutics.com
212 554 4484
3020 Carrington Mill Blvd., Morrisville, NY, 27560

Company Facts

3,990 Employees
IPO DateMay 3, 2010
CountryUS
Actively Trading

Frequently Asked Questions